Director, Clinical BiomarkerCSL BehringKing of Prussia, Pennsylvania, United States
PB1178 - Validation of a neutralizing antibody (NAb) assay with extended reportable range for etranacogene dezaparvovec, an adeno-associated virus serotype 5 (AAV5)-based gene therapy for adult hemophilia B
Tuesday, June 25, 202413:45 – 14:45 ICT
